查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1467745

2024-2032 年非酒精性脂肪性肝炎市场（按药物类型、疾病原因、销售管道、最终用户和地区）

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

2023年全球非酒精性脂肪性肝炎（NASH）IMARC Group规模达16亿美元。 。 NASH 盛行率不断上升、人们对早期诊断和治疗的认识不断提高，以及人工智慧 (AI) 和机器学习 (ML) 技术的融合是推动市场发展的一些关键因素。

非酒精性脂肪性肝炎（NASH）是指由胰岛素阻抗、过重和代谢症候群引起的进行性非酒精性脂肪肝病（NAFLD）。其症状包括疲劳无力、体重减轻、黄疸、皮肤搔痒、蜘蛛网状静脉、肝臟肿大、注意力不集中、积液以及腹部不适（例如疼痛和肿胀）。它可以透过多种技术进行诊断，例如体检、血液检查、肝臟活检、磁振造影 (MRI)、超音波和电脑断层扫描 (CT) 扫描。 NASH 治疗包括药物治疗、肝臟移植和各种生活方式的改变，例如定期运动和健康饮食。这些治疗方法有助于减少肝臟脂肪堆积、改善肝功能、减少发炎并最大限度地减少肝损伤。它们还可以提高患者的生活质量，改善长期结果，并可以更好地管理其他健康问题，例如肥胖和高血压。

非酒精性脂肪性肝炎 (NASH) 市场趋势：

由于遗传、久坐的生活方式、不健康的饮食习惯、肥胖和第 2 型糖尿病，NASH 盛行率不断上升，是推动市场成长的关键因素之一。与此一致，NASH治疗被患者广泛采用，以缓解症状、延长寿命、防止过早死亡、改善肝臟健康并促进整体福祉，这反过来又推动了市场成长。此外，大众对早期诊断和治疗NASH 的认识不断提高，以减少医疗费用，消除肝臟移植的需要，并预防未来的併发症，如高血压、心血管疾病(CVD)、癌症、肝硬化和肝臟疾病。此外，利用非侵入性成像技术（例如 MRI 和瞬时弹性成像 (TE)）来监测和诊断 NASH，从而提高患者的舒适度、提高依从性、降低併发症风险并改善临床结果，对市场成长产生积极影响。除此之外，人工智慧（AI）和机器学习（ML）的整合来开发个人化治疗、提高诊断准确性和预测疾病进展也有利于市场成长。此外，政府实施的各种旨在提供高品质治疗和支持先进疗法开发的措施正在推动市场成长。其他因素，包括老年人口的增加、医疗保健支出的增加、广泛的研发 (R&D) 活动、医疗保健行业的显着增长以及对非侵入性治疗方案的需求不断增加，预计将推动市场成长。

本报告回答的关键问题

  • 全球非酒精性脂肪性肝炎（NASH）市场有多大？
  • 2024-2032年全球非酒精性脂肪性肝炎（NASH）市场的预期成长率为何？
  • 推动全球非酒精性脂肪性肝炎（NASH）市场的关键因素是什么？
  • COVID-19 对全球非酒精性脂肪性肝炎 (NASH) 市场有何影响？
  • 根据药物类型，全球非酒精性脂肪性肝炎 (NASH) 市场的细分如何？
  • 根据疾病原因，全球非酒精性脂肪性肝炎 (NASH) 市场的细分如何？
  • 根据销售管道，全球非酒精性脂肪性肝炎 (NASH) 市场的细分情况如何？
  • 基于最终用户的全球非酒精性脂肪性肝炎 (NASH) 市场的细分情况如何？
  • 全球非酒精性脂肪性肝炎（NASH）市场的关键地区有哪些？
  • 谁是全球非酒精性脂肪性肝炎 (NASH) 市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球非酒精性脂肪性肝炎 (NASH) 市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 维生素E和吡格列酮
    • 市场走向
    • 市场预测
  • 奥卡利瓦
    • 市场走向
    • 市场预测
  • 埃拉菲布拉诺
    • 市场走向
    • 市场预测
  • 塞隆塞提布
    • 市场走向
    • 市场预测
  • 塞尼奇韦罗
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依疾病原因

  • 高血压
    • 市场走向
    • 市场预测
  • 心臟病
    • 市场走向
    • 市场预测
  • 高血脂
    • 市场走向
    • 市场预测
  • 2型糖尿病
    • 市场走向
    • 市场预测
  • 肥胖
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依销售管道

  • 医院药房
    • 市场走向
    • 市场预测
  • 线上提供者
    • 市场走向
    • 市场预测
  • 零售药房
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 诊所
    • 市场走向
    • 市场预测
  • 家庭护理设置
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Algernon Pharmaceuticals
    • Galmed Pharmaceuticals Ltd
    • Intercept Pharmaceuticals Inc.
    • Zydus Lifesciences Limited
Product Code: SR112024A7397

The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

Non-Alcoholic Steatohepatitis (NASH) Market Trends:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-alcoholic steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug type, disease cause, sales channel, and end user.

Drug Type Insights:

Vitamin E and Pioglitazone

Ocaliva

Elafibranor

Selonsertib

Cenicriviroc

Others

The report has provided a detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the drug type. This includes Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and others. According to the report, vitamin E and pioglitazone represented the largest segment.

Disease Cause Insights:

Hypertension

Heart Disease

High Blood Lipid

Type 2 Diabetes

Obesity

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the disease cause has also been provided in the report. This includes hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. According to the report, obesity accounted for the largest market share.

Sales Channel Insights:

Hospital Pharmacy

Online Providers

Retail Pharmacy

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the sales channel has also been provided in the report. This includes hospital pharmacy, online providers, and retail pharmacy. According to the report, retail pharmacy accounted for the largest market share.

End User Insights:

Hospitals

Clinics

Homecare Settings

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the end user has also been provided in the report. This includes hospitals, clinics, and homecare settings. According to the report, clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 2. What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2024-2032?
  • 3. What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 4. What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 5. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
  • 6. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
  • 7. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
  • 8. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
  • 9. What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 10. Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2023
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2023
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million US$), 2024-2032
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million US$), 2024-2032
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players